Standout Papers

Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label... 2020 2026 2022 2024402
  1. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial (2020)
    Shukui Qin, Zhenggang Ren et al. The Lancet Oncology

Immediate Impact

56 standout
Sub-graph 1 of 21

Citing Papers

Hepatocellular carcinoma: signaling pathways and therapeutic advances
2025 Standout
Expanded ROS Generation and Hypoxia Reversal: Excipient‐free Self‐assembled Nanotheranostics for Enhanced Cancer Photodynamic Immunotherapy
2024 Standout
1 intermediate paper

Works of Zhendong Chen being referenced

Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial
2020 Standout

Author Peers

Author Last Decade Papers Cites
Zhendong Chen 363 153 204 319 28 752
Alejandra Negro 482 119 213 382 32 825
Deborah Lehrer 232 208 87 360 21 694
Hao Xing 256 177 192 499 28 909
Joerg Trojan 306 214 163 313 30 914
Xiaochu Yan 288 247 133 206 33 780
Salvatore Patanè 197 383 140 193 36 748
Yefa Yang 243 219 144 346 39 797
Takehiro Hayashi 323 388 123 275 44 916
Deyu Guo 327 385 115 197 37 925
Gudrun Zulehner 273 404 57 143 42 922

All Works

Loading papers...

Rankless by CCL
2026